European Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
11 juil. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphoma Approval is based on results from the phase I/II...
Four-year follow up data for Roche’s Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk
30 juin 2023 11h50 HE
|
F. Hoffmann-La Roche Ltd
Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children with Type 1 SMANinety-one percent of children were alive at month 48More than 95% maintained the...
FDA approves Roche’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma
16 juin 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1.5 years (18.4 months)1Given over a fixed...
Roche awarded WHO prequalification for the cobas® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries
13 juin 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10...
New data show Roche’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)
09 juin 2023 08h45 HE
|
F. Hoffmann-La Roche Ltd
The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5...
Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
17 mai 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS)...
FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
09 mai 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was...
Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems
04 mai 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
The Institute of Human Biology aims to better predict which drug candidates are safe and most effective in patients by evolving and increasing the use of human model systems. Human model systems are...
CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
26 avr. 2023 12h50 HE
|
F. Hoffmann-La Roche Ltd
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
26 avr. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 26 April 2023 As expected, significantly lower demand for COVID-19 tests leads to a decrease in Group sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this...